Integrated BioTherapeutic Vaccines, Inc. is a wholly owned subsidiary of Integrated BioTherapeutics, Inc. (IBT). IBV’s mission is to foster the successful development of IBT-V02, a multi-component vaccine against Staphylococcus aureus, in particular multi-drug resistant S. aureus (MRSA), and other vaccine products in preparation for either out-licensing or forging strategic partnerships that lead to successful commercialization.